Quarterly report pursuant to Section 13 or 15(d)

Restatement of Condensed Consolidated Balance Sheet and Related Statements of Operations and Cash Flows - Schedule of Restatement (Details)

v3.8.0.1
Restatement of Condensed Consolidated Balance Sheet and Related Statements of Operations and Cash Flows - Schedule of Restatement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Total other income (expense), net $ 1,290 $ (904)  
Total net loss/comprehensive loss $ (512) (3,388)  
Deemed dividend related to beneficial conversion feature and accretion of a discount Series A convertible preferred stock    
Net loss attributable to common stockholders $ (512) $ (3,388)  
Net loss per share attributable to common stockholders Basic and diluted $ (0.18) $ (3.63)  
Weighted average common shares outstanding: Basic and diluted 2,826,469 932,771  
Common stock, $0.01 par value $ 30   $ 22
Additional paid-in capital 225,432   222,513
Accumulated deficit (211,551)   (211,300)
Total stockholders' equity 13,911   11,235
Derivative liabilities, current portion 2,179   $ 3,137
Scenario, Previously Reported [Member]      
Total other income (expense), net (348)    
Total net loss/comprehensive loss $ (2,150)    
Deemed dividend related to beneficial conversion feature and accretion of a discount Series A convertible preferred stock    
Net loss attributable to common stockholders $ (2,150)    
Net loss per share attributable to common stockholders Basic and diluted $ (0.06)    
Weighted average common shares outstanding: Basic and diluted 2,826,469    
Common stock, $0.01 par value $ 30    
Additional paid-in capital 231,345    
Accumulated deficit (215,285)    
Total stockholders' equity 16,090    
Derivative liabilities, current portion